Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Pasi Antero Janne, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Pasi Janne and Alice Shaw.
Connection Strength

0.473
  1. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013 Jan; 14(1):38-47.
    View in: PubMed
    Score: 0.140
  2. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011 May 20; 29(15_suppl):7514.
    View in: PubMed
    Score: 0.126
  3. U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 Sep 15; 26(18):4785-4794.
    View in: PubMed
    Score: 0.059
  4. Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 10 31; 6.
    View in: PubMed
    Score: 0.049
  5. KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 02 01; 6.
    View in: PubMed
    Score: 0.047
  6. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23.
    View in: PubMed
    Score: 0.028
  7. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S107-12.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.